Teleflex Incorporated Stock News

Teleflex Incorporated ( TFX ) Q3 2025 Earnings Call November 6, 2025 8:00 AM EST Company Participants Lawrence Keusch - Vice President of Investor Relations & Strategy Development Liam Kelly - Chairman, President & CEO John Deren - Executive VP & CFO Conference Call Participants Michael Matson - Needham & Company, LLC, Research Division Matthew Taylor - Jefferies LLC, Research Division Jayson B...

WAYNE, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable December 15, 2025, to shareholders of record at the close of business on November 14, 2025.

WAYNE, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the third quarter ended September 28, 2025.

WAYNE, Pa., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its third quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, November 6, 2025.

The Trial Evaluates a Combined PCI Approach Using Drug-Coated Balloons and Drug-Eluting Stents The Trial Evaluates a Combined PCI Approach Using Drug-Coated Balloons and Drug-Eluting Stents

Teleflex Incorporated (NYSE:TFX ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 3:20 PM EDT Company Participants Liam Kelly - Chairman, President & CEO Conference Call Participants Patrick Wood - Morgan Stanley, Research Division Presentation Patrick Wood MD of Equity Research All right. Let's kick it off.

WAYNE, Pa., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Management of Teleflex Incorporated (NYSE: TFX) will be presenting at the Morgan Stanley 23rd Annual Global Healthcare Conference at the Sheraton New York Times Square, on Tuesday, September 9, 2025, at 3:20 p.m. (ET).

Innovative hyaluronic acid technology delivers enhanced control and precision, significantly lowering the risk of rectal toxicity during prostate radiation treatment. 1 - 4 Initial cases have now been performed in Japan.